Explore the words cloud of the X-10 Pathology project. It provides you a very rough idea of what is the project "X-10 Pathology" about.
The following table provides information about the project.
GRADEMI BIOTECH SRL
|Coordinator Country||Italy [IT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-08-01 to 2016-12-31|
Take a look of project's partnership.
|1||GRADEMI BIOTECH SRL||IT (BOLOGNA)||coordinator||50˙000.00|
With the market introduction of X-10 Pathology we aim to shape a new era of healthcare and drive clinical testing to play a major role in prevention, diagnosis and disease monitoring. We are targeting a group of inflammatory-related pathologies affecting about 15-20% of the world population, for which no specific diagnostic assay is currently available. We want to stop the spiral of repeated tests and specialist consultations and offer patients a simple and inexpensive test on a powerful device, to have their disease identified and monitored in an accurate and timely fashion. To honour our mission we have developed X-10 Pathology, the first-ever device with demonstrated diagnostic capability on the specific causes of inflammatory conditions. Born from the synergy of cutting edge technical and clinical expertise, our standalone platform aims to provide a simple, cost-effective device that empowers also non-specialized personnel to provide fast and specific answers to patients with a minimally invasive test, also in developing Countries. We believe that the disruptive concept of X-10 Pathology has the enormous potential of empowering the healthcare system in its race to balance limited resources with the need of reliable and cost-effective diagnosis and treatment to a growing and ageing global population. Considering the advanced stage of development of our product and the successful outcome of preliminary clinical tests, we target the launch of X-10 Pathology in 2018, after obtaining regulatory approval. By joining the global market of In Vitro Diagnostics we will contribute to the growth of this sector, expected to reach € 66 billion by 2020. A feasibility study covering the technological, commercial and financial aspects will enable us to finalize our business plan and secure our steps towards the successful market launch.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "X-10 PATHOLOGY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "X-10 PATHOLOGY" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Integrating and decentralising diabetes and hypertension services in AfricaRead More